Morgan Stanley Buys 7,000 Shares of Fibrocell Science Inc (NASDAQ:FCSC)
Morgan Stanley raised its stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 13.2% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 59,900 shares of the company’s stock after acquiring an additional 7,000 shares during the period. Morgan Stanley owned approximately 0.61% of Fibrocell Science worth $114,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Bank of Montreal Can bought a new position in Fibrocell Science during the 2nd quarter valued at about $71,000. Renaissance Technologies LLC lifted its stake in Fibrocell Science by 38.0% during the 2nd quarter. Renaissance Technologies LLC now owns 740,454 shares of the company’s stock valued at $1,407,000 after acquiring an additional 204,015 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Fibrocell Science by 140.6% during the 2nd quarter. Vanguard Group Inc. now owns 394,456 shares of the company’s stock valued at $749,000 after acquiring an additional 230,522 shares during the period. Institutional investors and hedge funds own 32.92% of the company’s stock.
Several equities analysts have issued reports on FCSC shares. Canaccord Genuity cut shares of Fibrocell Science from a “buy” rating to a “hold” rating in a research note on Monday, September 16th. HC Wainwright lowered shares of Fibrocell Science from a “buy” rating to a “neutral” rating and set a $3.00 price target for the company. in a research report on Friday, September 13th. Zacks Investment Research raised shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Wednesday. Finally, ValuEngine lowered shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 2nd.
Fibrocell Science (NASDAQ:FCSC) last posted its earnings results on Wednesday, August 14th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $1.30. The firm had revenue of $21.79 million for the quarter. As a group, equities research analysts anticipate that Fibrocell Science Inc will post 0.1 EPS for the current year.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
Read More: Bond
Want to see what other hedge funds are holding FCSC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fibrocell Science Inc (NASDAQ:FCSC).
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.